- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT04697784
Post-Zulassungsstudie des TREO Abdominal Stent-Graft Systems (TREO PAS)
Post-Zulassungsstudie des TREO Abdominal Stent-Graft Systems (P190015) bei Patienten mit infrarenalen abdominalen Aorten- und aortoiliakalen Aneurysmen
The purpose of this study is to determine the long-term performance of the TREO Abdominal Stent-Graft as a treatment for patients with Infrarenal Abdominal Aortic Aneurysms or Aorto-iliac Aneurysms.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
This is a prospective, multi-center, non-randomized, single-arm, post-market, non-interventional study of treatment with the TREO Abdominal Stent-Graft in subjects with Infrarenal Abdominal Aortic Aneurysms or Aorto-iliac Aneurysms. The study will include a minimum of 300 subjects treated with the TREO Abdominal Stent-Graft at up to 55 investigational sites in the US.
The primary objective is the collection of real world safety and effectiveness outcomes of the TREO Abdominal Stent-Graft System in an all-comers population eligible for the endovascular treatment of AAA in routine clinical practice, with emphasis on subjects that experience a device stent-strut or barb fracture.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
Arizona
-
Phoenix, Arizona, Vereinigte Staaten, 85006
- Vascular Surgery Specialists
-
Tucson, Arizona, Vereinigte Staaten, 85718
- Pima Heart and Vascular
-
-
California
-
Fresno, California, Vereinigte Staaten, 93701
- University of California, San Francisco-Fresno
-
La Jolla, California, Vereinigte Staaten, 92037
- University of California, San Diego
-
San Diego, California, Vereinigte Staaten, 92161
- VA San Diego
-
-
Colorado
-
Aurora, Colorado, Vereinigte Staaten, 80045
- University of Colorado Anschutz
-
-
Connecticut
-
New Haven, Connecticut, Vereinigte Staaten, 06520
- Yale University
-
-
District of Columbia
-
Washington D.C., District of Columbia, Vereinigte Staaten, 20010
- Medstar Washington Hospital Center
-
-
Florida
-
Gainesville, Florida, Vereinigte Staaten, 32610
- University of Florida
-
Gainesville, Florida, Vereinigte Staaten, 32608
- Malcom Randall VA Medical Center
-
Pensacola, Florida, Vereinigte Staaten, 32504
- Coastal Vascular and Interventional
-
Tampa, Florida, Vereinigte Staaten, 33606
- University of South Florida / Tampa General Hospital
-
-
Georgia
-
Atlanta, Georgia, Vereinigte Staaten, 30342
- Northside Hospital
-
Atlanta, Georgia, Vereinigte Staaten, 30309
- Piedmont Heart Institute
-
-
Iowa
-
Iowa City, Iowa, Vereinigte Staaten, 52242
- University of Iowa Hospital and Clinic
-
-
Massachusetts
-
Boston, Massachusetts, Vereinigte Staaten, 02114
- Massachusetts General Hospital
-
Boston, Massachusetts, Vereinigte Staaten, 02111
- Tufts Medical Center
-
-
Michigan
-
Bay City, Michigan, Vereinigte Staaten, 48708
- McLaren Bay Region
-
Detroit, Michigan, Vereinigte Staaten, 48202
- Henry Ford Hospital
-
-
Minnesota
-
Minneapolis, Minnesota, Vereinigte Staaten, 55407
- Minneapolis Heart Institute Foundation
-
-
Missouri
-
St Louis, Missouri, Vereinigte Staaten, 63110
- Barnes Jewish Hospital at Washington University
-
-
New Jersey
-
Hackensack, New Jersey, Vereinigte Staaten, 07601
- Hackensack University Medical Center
-
New Brunswick, New Jersey, Vereinigte Staaten, 08901
- Rutgers Robert Wood Johnson Medical Center
-
-
New York
-
New York, New York, Vereinigte Staaten, 10075
- Lenox Hill Hospital / Northwell Health
-
Stony Brook, New York, Vereinigte Staaten, 11794-8191
- Stony Brook Medical Center
-
Syracuse, New York, Vereinigte Staaten, 13210
- SUNY Upstate Medical University
-
The Bronx, New York, Vereinigte Staaten, 10467
- Montefiore Medical Center
-
-
North Carolina
-
Asheville, North Carolina, Vereinigte Staaten, 27607
- Mission Health
-
Greenville, North Carolina, Vereinigte Staaten, 27834
- East Carolina University
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Vereinigte Staaten, 73104
- University of Oklahoma Health Sciences Center
-
-
Oregon
-
Portland, Oregon, Vereinigte Staaten, 97239
- Oregon Health and Science University
-
Portland, Oregon, Vereinigte Staaten, 97239
- VA Portland Healthcare System
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19140
- Temple University Hospital
-
Pittsburgh, Pennsylvania, Vereinigte Staaten, 15232
- University of Pittsburgh Medical Center
-
-
Tennessee
-
Kingsport, Tennessee, Vereinigte Staaten, 37660
- Wellmont Cardiology Services
-
-
Texas
-
Austin, Texas, Vereinigte Staaten, 78756
- St. David's Healthcare (Cardiothoracic and Vascular Surgeons)
-
-
Utah
-
Salt Lake City, Utah, Vereinigte Staaten, 84132
- University of Utah Hospital
-
-
Virginia
-
Norfolk, Virginia, Vereinigte Staaten, 22042
- Sentara Heart Hospital
-
Richmond, Virginia, Vereinigte Staaten, 23282
- Virginia Commonwealth University
-
-
Wisconsin
-
Milwaukee, Wisconsin, Vereinigte Staaten, 53226
- Medical College of Wisconsin
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Willing and able to comply with all study procedures and visits.
- Written informed consent to participate in the study.
- Patient's aneurysm can be treated with the TREO Abdominal Stent-Graft System.
- Adequate data (medical records/imaging studies) available to analyze the primary endpoints for patients enrolled retrospectively.
Exclusion Criteria:
• Medical, social or psychological problems that, in the opinion of the investigator, preclude patient from receiving treatment with the TREO Abdominal Stent-Graft System.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Subjects who receive the TREO Abdominal Stent-Graft System
Eligible subjects will be implanted with the TREO Abdominal Stent-Graft System. |
The TREO Abdominal Stent-Graft System is intended for the treatment of infrarenal abdominal aortic aneurysms with or without iliac involvement. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Incidence of stent-strut fracture or barb separation as confirmed by the Imaging Core Laboratory.
Zeitfenster: Through 5 Years post-procedure
|
Incidence of fracture in a stent-strut or separation of one or more proximal fixation barbs as confirmed by the Imaging Core Laboratory upon review of post-implant imaging studies. |
Through 5 Years post-procedure
|
|
Incidence of secondary intervention for adverse events related to or caused as a result of stent-strut fracture or barb separation.
Zeitfenster: Through 5 Years post-procedure
|
Incidence of secondary intervention for adverse events related to or caused as a result of a fracture in a stent-strut or separation of one or more proximal fixation barbs. Relatedness to the device will be confirmed by the Clinical Events Committee (CEC) through review of available treatment and procedure records and reports of imaging studies. |
Through 5 Years post-procedure
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Number of participants with technical success at the conclusion of the index procedure
Zeitfenster: Through 5 Years post-procedure
|
Defined as the following:
|
Through 5 Years post-procedure
|
|
Major Adverse Events
Zeitfenster: Through 5 Years post-procedure
|
Incidence of the following Major Adverse Events
|
Through 5 Years post-procedure
|
|
Incidence of procedure-related clinical utility measures
Zeitfenster: Through 5 Years post-procedure
|
Reporting of procedural data collected during implant of the TREO Abdominal Stent-Graft System including: Procedure time (minutes), Fluoroscopy time (minutes), Contrast volume (mL), Access method (i.e. percutaneous, surgical cut down), Length of ICU stay (hours), Length of hospital stay post-procedure (days), Anesthesia Type. |
Through 5 Years post-procedure
|
|
Incidence of procedure-related complications
Zeitfenster: Through 5 Years post-procedure
|
Incidence of adverse events occurring during or following the implant determined by the CEC to be procedure-related. |
Through 5 Years post-procedure
|
|
Incidence of successful aneurysm treatment
Zeitfenster: 12 months post-implant
|
Successful aneurysm treatment is defined as:
|
12 months post-implant
|
|
Incidence of all-cause mortality
Zeitfenster: Through 5 Years post-procedure
|
Rate of mortality attributed to any causality as confirmed by the CEC. |
Through 5 Years post-procedure
|
|
Incidence of aneurysm-related mortality
Zeitfenster: Through 5 Years post-procedure
|
Rate of mortality attributed to the following causes as confirmed by the CEC: death due to a rupture, death within 30 days or prior to hospital discharge from primary procedure, or death within 30 days or prior to hospital discharge for a secondary procedure designed to treat the original aneurysm. |
Through 5 Years post-procedure
|
|
Incidence of aneurysm rupture
Zeitfenster: Through 5 Years post-procedure
|
Incidence of rupture of the native aneurysm sac post-implantation of the endograft as confirmed by the CEC. |
Through 5 Years post-procedure
|
|
Incidence of secondary interventions.
Zeitfenster: Through 5 Years post-procedure
|
Incidence of secondary procedures designed to treat or repair the original aneurysm treated with the TREO Abdominal Stent-Graft System |
Through 5 Years post-procedure
|
|
Incidence of conversion to open surgical repair.
Zeitfenster: Through 5 Years post-procedure
|
Incidence of conversion to open surgical AAA repair during the initial EVAR procedure secondary to any procedure-related complications as determined by the CEC. |
Through 5 Years post-procedure
|
|
Incidence of stent-graft occlusion (i.e., loss of patency)
Zeitfenster: Through 5 Years post-procedure
|
Incidence of stent-graft occlusion defined as the unintentional obstruction of the vascular/endograft lumen with minor obstruction (0-25%), minimal obstruction (26-74%), moderate obstruction (75-99%) or occlusion (100%) as confirmed by the Imaging Core Lab due to causes such as twisting or kinking of the prosthesis, oversizing and fabric pleating, or failure of the implant to fully open, or to mural thrombus deposition. |
Through 5 Years post-procedure
|
|
Incidence of device stenosis or kink
Zeitfenster: Through 5 Years post-procedure
|
Incidence of stenosis or kinking of the TREO Stent-Graft as confirmed by the Imaging Core Lab. |
Through 5 Years post-procedure
|
|
Incidence of loss of device integrity
Zeitfenster: Through 5 Years post-procedure
|
Incidence of changes in the structural integrity in a material component of the stent-graft such as a stent-strut fracture or separation of the proximal fixation barbs as confirmed by the Imaging Core Lab. |
Through 5 Years post-procedure
|
|
Incidence of aneurysm enlargement (>5mm as compared to 30-day imaging).
Zeitfenster: Through 5 Years post-procedure
|
Incidence of the increase in the aneurysm sac diameter > 5 mm at post-implant follow-up visits relative to the diameter determined at the first post-procedural imaging study, as confirmed by the Imaging Core Lab. |
Through 5 Years post-procedure
|
|
Incidence of stent-graft migration (>10mm as compared to 30-day imaging)
Zeitfenster: Through 5 Years post-procedure
|
Incidence of the longitudinal movement of all or part of a stent or attachment system for a distance of >10 mm relative to anatomical landmarks that were determined at the first post-procedural imaging study as confirmed by the Imaging Core Lab. |
Through 5 Years post-procedure
|
|
Incidence of Type I, II, III, IV or V Endoleaks
Zeitfenster: Through 5 Years post-procedure
|
Incidence of Type I, II, III, IV or V Endoleaks defined as the persistence of blood flow outside the lumen of the stent-graft but within the native aorta or adjacent vascular segment being treated by the stent-graft as determined by the Imaging Core Lab. |
Through 5 Years post-procedure
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Studienleiter: Gretchen Wild, Terumo Aortic
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- IP-0021-20
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .